Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075005 | 0.88 | MAPT (0.32) | DRD2LMNA | |
| SCHEMBL26494108 | 0.86 | OPRL1 (0.35) | — | |
| SCHEMBL20330263 | 0.85 | SMN1; SMN2 (0.33) | DAO | |
| SCHEMBL13519629 | 0.80 | DAO (0.42) | DRD2DAO | |
| SCHEMBL25881821 | 0.79 | TSHR (0.32) | — | |
| SCHEMBL13860747 | 0.78 | HRH3 (0.35) | — | |
| SCHEMBL15292552 | 0.78 | HRH3 (0.36) | — | |
| SCHEMBL21472823 | 0.76 | CYP2D6 (0.33) | — | |
| SCHEMBL26494117 | 0.76 | DAO (0.33) | DAO | |
| SCHEMBL4546631 | 0.75 | RORC (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | DRD2 3855/4885DAO 1427/4885LMNA 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.